Full TitleStandard Infusion Carboplatin Versus Prophylactic Extended Infusion Carboplatin in the Treatment of Patients with Recurrent, Ovary, Fallopian Tube, and Primary Peritoneal Cancer
Patients who have recurrent ovarian, fallopian tube, or peritoneal cancer are often treated with several drugs. Carboplatin is one that seems to work for many treatment cycles. Even though it may work against the cancer, patients can become allergic to it. If that happens, treatment with the drug usually needs to be stopped.
Some patients have received carboplatin over three hours instead of 30 minutes. They had fewer allergic reactions than expected. Doctors do not know if this was because of the way they got carboplatin or because of some other factor.
The purpose of this study is to see if giving carboplatin over three hours prevents allergic reactions to the drug, and to see if giving certain other medications before the carboplatin can help reduce allergies. Some patients may receive other chemotherapy drugs as part of their treatment in addition to carboplatin.
To be eligible for this study, patients must meet several criteria, including but not limited to the following:
- Patients must have ovarian, fallopian tube, or peritoneal cancer that has recurred following one or two regimens of prior platinum-based chemotherapy.
- Disease must have relapsed six or more months following completion of platinum-based therapy.
- Patients who had a prior allergic reaction to carboplatin or cisplatin may not participate.
- Patients must be able to be ambulatory for more than half of their normal waking hours.
- Patients must be age 21 or older.
For more information about this study and to inquire about eligibility, please contact Dr. Roisin O’Cearbhaill at 646-888-4227.